Expression of pituitary tumor-transforming gene in endometrial cancer as a prognostic marker

J. W. Kim, Jae Yun Song, J. M. Lee, Jae Kwan Lee, Nak Woo Lee, B. W. Yeom, K. W. Lee

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The pituitary tumor-transforming gene (PTTG) is a novel oncogene expressed abundantly in most tumors, regulates basic fibroblast growth factor secretion, and induces angiogenesis. The objective of this study is to compare the expression rate of PTTG in endometrial cells, to correlate the level of expression of PTTG with the clinicopathologic parameters and overall survival, and to evaluate the possible use of PTTG as a prognostic marker of endometrial cancer. Forty patients diagnosed with endometrial cancer, 20 patients with endometrial hyperplasia, and 20 patients with normal endometrial tissues were included in the study. Immunohistochemical analyses on paraffin-embedded blocks were performed using a polyclonal anti-PTTG antibody. The decrease in expression of cytoplasmic and nuclear PTTG seen for endometrial cancer cells was statistically significant (P < 0.05). Cytoplasmic PTTG expression correlated with expression of progesterone receptor (P = 0.009) and FGF-2 (P = 0.007) but not with other parameters such as the expression of estrogen receptor, tumor grade, and surgical stage. Nuclear PTTG expression did not correlate with any parameters. The mean survival of patients with positive and negative cytoplasmic PTTG expression was 40.8 and 48.6 months (P = 0.78). In nuclear PTTG expression, the survival was 20.0 and 51.8 months, respectively (P = 0.04). Cytoplasmic PTTG expression was not associated with survival. Patients with nuclear PTTG overexpression showed a significant decrease in survival. The use of PTTG as a prognostic marker for endometrial cancer needs further investigation.

Original languageEnglish
Pages (from-to)1352-1359
Number of pages8
JournalInternational Journal of Gynecological Cancer
Volume18
Issue number6
DOIs
Publication statusPublished - 2008 Nov 1

Fingerprint

Pituitary Neoplasms
Endometrial Neoplasms
Oncogenes
Gene Expression
Survival
Fibroblast Growth Factor 2
Endometrial Hyperplasia
Progesterone Receptors
Estrogen Receptors
Paraffin
Neoplasms

Keywords

  • Endometrial cancer
  • FGF-2
  • PTTG

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynaecology

Cite this

Expression of pituitary tumor-transforming gene in endometrial cancer as a prognostic marker. / Kim, J. W.; Song, Jae Yun; Lee, J. M.; Lee, Jae Kwan; Lee, Nak Woo; Yeom, B. W.; Lee, K. W.

In: International Journal of Gynecological Cancer, Vol. 18, No. 6, 01.11.2008, p. 1352-1359.

Research output: Contribution to journalArticle

@article{50b7c7cf937145fca448b938b00005a9,
title = "Expression of pituitary tumor-transforming gene in endometrial cancer as a prognostic marker",
abstract = "The pituitary tumor-transforming gene (PTTG) is a novel oncogene expressed abundantly in most tumors, regulates basic fibroblast growth factor secretion, and induces angiogenesis. The objective of this study is to compare the expression rate of PTTG in endometrial cells, to correlate the level of expression of PTTG with the clinicopathologic parameters and overall survival, and to evaluate the possible use of PTTG as a prognostic marker of endometrial cancer. Forty patients diagnosed with endometrial cancer, 20 patients with endometrial hyperplasia, and 20 patients with normal endometrial tissues were included in the study. Immunohistochemical analyses on paraffin-embedded blocks were performed using a polyclonal anti-PTTG antibody. The decrease in expression of cytoplasmic and nuclear PTTG seen for endometrial cancer cells was statistically significant (P < 0.05). Cytoplasmic PTTG expression correlated with expression of progesterone receptor (P = 0.009) and FGF-2 (P = 0.007) but not with other parameters such as the expression of estrogen receptor, tumor grade, and surgical stage. Nuclear PTTG expression did not correlate with any parameters. The mean survival of patients with positive and negative cytoplasmic PTTG expression was 40.8 and 48.6 months (P = 0.78). In nuclear PTTG expression, the survival was 20.0 and 51.8 months, respectively (P = 0.04). Cytoplasmic PTTG expression was not associated with survival. Patients with nuclear PTTG overexpression showed a significant decrease in survival. The use of PTTG as a prognostic marker for endometrial cancer needs further investigation.",
keywords = "Endometrial cancer, FGF-2, PTTG",
author = "Kim, {J. W.} and Song, {Jae Yun} and Lee, {J. M.} and Lee, {Jae Kwan} and Lee, {Nak Woo} and Yeom, {B. W.} and Lee, {K. W.}",
year = "2008",
month = "11",
day = "1",
doi = "10.1111/j.1525-1438.2007.01168.x",
language = "English",
volume = "18",
pages = "1352--1359",
journal = "International journal of gynecological cancer : official journal of the International Gynecological Cancer Society",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Expression of pituitary tumor-transforming gene in endometrial cancer as a prognostic marker

AU - Kim, J. W.

AU - Song, Jae Yun

AU - Lee, J. M.

AU - Lee, Jae Kwan

AU - Lee, Nak Woo

AU - Yeom, B. W.

AU - Lee, K. W.

PY - 2008/11/1

Y1 - 2008/11/1

N2 - The pituitary tumor-transforming gene (PTTG) is a novel oncogene expressed abundantly in most tumors, regulates basic fibroblast growth factor secretion, and induces angiogenesis. The objective of this study is to compare the expression rate of PTTG in endometrial cells, to correlate the level of expression of PTTG with the clinicopathologic parameters and overall survival, and to evaluate the possible use of PTTG as a prognostic marker of endometrial cancer. Forty patients diagnosed with endometrial cancer, 20 patients with endometrial hyperplasia, and 20 patients with normal endometrial tissues were included in the study. Immunohistochemical analyses on paraffin-embedded blocks were performed using a polyclonal anti-PTTG antibody. The decrease in expression of cytoplasmic and nuclear PTTG seen for endometrial cancer cells was statistically significant (P < 0.05). Cytoplasmic PTTG expression correlated with expression of progesterone receptor (P = 0.009) and FGF-2 (P = 0.007) but not with other parameters such as the expression of estrogen receptor, tumor grade, and surgical stage. Nuclear PTTG expression did not correlate with any parameters. The mean survival of patients with positive and negative cytoplasmic PTTG expression was 40.8 and 48.6 months (P = 0.78). In nuclear PTTG expression, the survival was 20.0 and 51.8 months, respectively (P = 0.04). Cytoplasmic PTTG expression was not associated with survival. Patients with nuclear PTTG overexpression showed a significant decrease in survival. The use of PTTG as a prognostic marker for endometrial cancer needs further investigation.

AB - The pituitary tumor-transforming gene (PTTG) is a novel oncogene expressed abundantly in most tumors, regulates basic fibroblast growth factor secretion, and induces angiogenesis. The objective of this study is to compare the expression rate of PTTG in endometrial cells, to correlate the level of expression of PTTG with the clinicopathologic parameters and overall survival, and to evaluate the possible use of PTTG as a prognostic marker of endometrial cancer. Forty patients diagnosed with endometrial cancer, 20 patients with endometrial hyperplasia, and 20 patients with normal endometrial tissues were included in the study. Immunohistochemical analyses on paraffin-embedded blocks were performed using a polyclonal anti-PTTG antibody. The decrease in expression of cytoplasmic and nuclear PTTG seen for endometrial cancer cells was statistically significant (P < 0.05). Cytoplasmic PTTG expression correlated with expression of progesterone receptor (P = 0.009) and FGF-2 (P = 0.007) but not with other parameters such as the expression of estrogen receptor, tumor grade, and surgical stage. Nuclear PTTG expression did not correlate with any parameters. The mean survival of patients with positive and negative cytoplasmic PTTG expression was 40.8 and 48.6 months (P = 0.78). In nuclear PTTG expression, the survival was 20.0 and 51.8 months, respectively (P = 0.04). Cytoplasmic PTTG expression was not associated with survival. Patients with nuclear PTTG overexpression showed a significant decrease in survival. The use of PTTG as a prognostic marker for endometrial cancer needs further investigation.

KW - Endometrial cancer

KW - FGF-2

KW - PTTG

UR - http://www.scopus.com/inward/record.url?scp=55949134937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55949134937&partnerID=8YFLogxK

U2 - 10.1111/j.1525-1438.2007.01168.x

DO - 10.1111/j.1525-1438.2007.01168.x

M3 - Article

C2 - 18217976

AN - SCOPUS:55949134937

VL - 18

SP - 1352

EP - 1359

JO - International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

JF - International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

SN - 1048-891X

IS - 6

ER -